Clearside Biomedical enters royalty financing with HealthCare Royalty for up to $65M

Clearside Biomedical, Inc.

Upfront cash of $32.5M; additional $12.5M escrow tied to XIPERE sales milestone, plus up to $20M second milestone.
HealthCare Royalty receives royalties from XIPERE and SCS Microinjector license deals until 2.5x (or 3.4x) payback achieved.
Proceeds intended to support CLS-AX (axitinib injectable suspension) clinical program via suprachoroidal injection.
Deal excludes Clearside's internal pipeline and future in-licensed assets; non-dilutive capital.
Transaction expected to close in August 2022; JMP Securities acted as financial advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.